Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 1 crawled time : 13:00 save search
Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Oral Formulation of Dual GLP-1/GIP Receptor Agonist VK2735
Published: 2023-03-28 (Crawled : 13:00) - biospace.com/
VKTX | $63.38 -2.0% -2.04% 3M
|
Health Technology
|
| O: 34.98%
H: 25.83%
C: 25.43%
LGND | $72.59 0.1% 0.1% 140K
|
Health Technology
|
| O: -0.07%
H: 5.37%
C: 4.8%
vk2735 agonist therapeutics study phase 1
BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1 Trial for SHP2 Inhibitor BBP-398 in Combination with Bristol Myers Squibb’s OPDIVO® (nivolumab)
Published: 2023-03-23 (Crawled : 13:00) - biospace.com/
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 0.52%
H: 0.46%
C: -0.9%
BBIO | $24.74 -0.84% -0.85% 2M
|
Health Technology
|
| O: 0.62%
H: 5.65%
C: 5.11%
bbp-398 opdivo lung pharma cancer trial phase 1
FSD Pharma Announces Its Australian Entity Receives Approval to Proceed With Phase 1 Clinical Trial of Lucid-201, a Candidate for the Potential Treatment of Major Depressive Disorder
Published: 2023-03-22 (Crawled : 13:00) - biospace.com/
HUGE | $0.6167 1.22% 29K
|
Process Industries
|
| O: 0.65%
H: 3.21%
C: 0.0%
pharma candidate approval treatment trial potential phase 1 major depressive disorder
Journey Medical Corporation Announces Completion of Treatment Assessing Impact of DFD-29 (Minocycline Modified Release Capsules 40 mg) on Microbial Flora in a Separate Phase 1 Clinical Trial
Published: 2023-03-16 (Crawled : 13:00) - globenewswire.com
DERM | $3.45 -3.63% -3.77% 100K
|
|
| O: -4.96%
H: 15.3%
C: 10.07%
FBIO | $1.765 -2.49% -2.55% 190K
|
Health Technology
|
| O: 2.54%
H: 0.0%
C: 0.0%
dfd-29 corporation treatment impact medical trial phase 1
Sernova Announces Initial Islet Transplantation in First Two Patients Enrolled in Second Cohort of its U.S. Phase 1/2 Clinical Trial for Treatment of Type 1 Diabetes
Published: 2023-03-08 (Crawled : 13:00) - biospace.com/
SEOVF | $0.3295 15.67% 29K
|
Health Technology
|
| O: 1.27%
H: 4.0%
C: -2.5%
treatment trial diabetes phase 1
Werewolf Therapeutics Announces Initiation of Patient Dosing in Phase 1 Study of WTX-330
Published: 2023-02-24 (Crawled : 13:00) - globenewswire.com
HOWL | $5.91 0.68% 0.68% 120K
|
Professional, Scientific, and T...
|
| O: -1.64%
H: 8.67%
C: -12.33%
wtx-330 therapeutics study phase 1
Immunocore announces initial Phase 1 safety and pharmacodynamic activity data with first soluble TCR therapy for people living with HIV
Published: 2023-02-22 (Crawled : 13:00) - biospace.com/
IMCR | $55.71 1.77% 1.74% 450K
|
Manufacturing
|
| O: -1.52%
H: 2.86%
C: -0.17%
hiv therapy living phase 1
Century Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 ELiPSE-1 Trial Evaluating CNTY-101 in Relapsed or Refractory CD19 Positive B-cell Lymphomas
Published: 2023-02-08 (Crawled : 13:00) - biospace.com/
IPSC | $3.06 2.86% 2.78% 110K
|
Professional, Scientific, and T...
|
| O: 1.89%
H: 1.03%
C: -4.12%
cnty-101 lymphomas cd19 trial therapeutics positive phase 1
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MMP7 for Treatment of Idiopathic Pulmonary Fibrosis
Published: 2023-02-02 (Crawled : 13:00) - biospace.com/
ARWR | $22.33 -1.24% -1.25% 960K
|
Health Technology
|
| O: 1.3%
H: 3.52%
C: 3.52%
treatment fibrosis pharmaceuticals study phase 1
C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT1946, an Orally Bioavailable BiDAC™ Degrader, in BRAF V600 Mutant Solid Tumors
Published: 2023-01-30 (Crawled : 13:00) - biospace.com/
CCCC | $6.74 -2.46% -2.52% 1.7M
|
Health Technology
|
| O: -0.77%
H: 3.47%
C: 0.0%
cft1946 trial therapeutics tumors phase 1
Mersana Therapeutics Announces Initiation of Phase 1 Trial of XMT-2056 in HER2-Expressing Tumors
Published: 2023-01-25 (Crawled : 13:00) - globenewswire.com
MRSN | $3.255 -2.55% -2.61% 2.4M
|
Health Technology
|
| O: -0.6%
H: 0.76%
C: -0.46%
xmt-2056 trial therapeutics tumors her2- her2 phase 1
IGM Biosciences Announces Update on IGM-8444 Phase 1 Trial and Future Clinical Development
Published: 2023-01-09 (Crawled : 13:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 1.38%
H: 0.28%
C: 0.28%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 1.82%
H: 0.0%
C: 0.0%
IGMS | $7.2 -2.83% -2.92% 220K
|
Health Technology
|
| O: 10.09%
H: 1.73%
C: -1.29%
igm-8444 trial update phase 1
Sensei Biotherapeutics Announces Clinical Supply Agreement with Regeneron for Phase 1/2 Clinical Trial Evaluating SNS-101
Published: 2023-01-05 (Crawled : 13:00) - biospace.com/
SNSE | $1.03 4.79% 4.57% 24K
|
|
| O: -2.58%
H: 0.66%
C: -0.66%
sns-101 trial agreement phase 1
Surface Oncology Announces First Patient Dosed in a Phase 1/2 Study Evaluating SRF114, a Potential Best-In-Class Anti-CCR8 Antibody, in Patients with Advanced Solid Tumors
Published: 2023-01-05 (Crawled : 13:00) - biospace.com/
SURF | $1.07 -0.93% -1.41% 0
|
Health Technology
|
| O: 2.15%
H: 8.91%
C: 5.49%
srf114 tumors potential study phase 1
Jounce Therapeutics Presents INNATE Phase 1 and SELECT Clinical Trial data at the European Society of Medical Oncology Immuno-Oncology (ESMO - IO) Annual Congress
Published: 2022-12-08 (Crawled : 13:00) - globenewswire.com
JNCE | $1.88 -2.59% -1.85% 0
|
Health Technology
|
| O: 1.82%
H: 1.52%
C: -7.91%
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.09%
H: 1.98%
C: 1.82%
medical trial therapeutics phase 1
Bio-Path Holdings Announces First Patient Dosed in Phase 1/1b Clinical Trial of BP1001-A in Solid Tumors
Published: 2022-12-07 (Crawled : 13:00) - biospace.com/
BPTH | News 0 d | $4.17 -0.71% -0.96% 2.1M
|
Health Technology
|
| O: 5.88%
H: 0.0%
C: -11.11%
bp1001 trial tumors phase 1
Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-3828136
Published: 2022-12-07 (Crawled : 13:00) - globenewswire.com
CYTK | $67.49 0.73% 0.73% 1.5M
|
Health Technology
|
| O: -0.38%
H: 2.03%
C: 0.49%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 0.04%
H: 0.89%
C: 0.83%
ck-3828 study phase 1
Exscientia Receives First CTA Approval to Initiate IGNITE-AI, a Phase 1/2 Trial of EXS-21546 in Patients with Advanced Solid Tumours
Published: 2022-11-28 (Crawled : 13:00) - biospace.com/
EVO | $7.15 -0.7% 19K
|
Manufacturing
|
| O: -1.91%
H: 1.49%
C: -0.34%
EXAI | $4.24 -2.75% -2.83% 370K
|
|
| O: 3.66%
H: 0.67%
C: -6.4%
exs-2154 trial approval phase 1
Sernova Announces First Two Patients Implanted with Cell Pouch™ in the Second Cohort of its US Phase 1/2 Clinical Trial for Type 1 Diabetes
Published: 2022-11-17 (Crawled : 13:00) - biospace.com/
SEOVF | $0.3295 15.67% 29K
|
Health Technology
|
| O: -1.71%
H: 0.0%
C: -3.87%
trial diabetes phase 1
Aerovate Therapeutics Publishes Results of Phase 1 Study Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension in ERJ Open Research
Published: 2022-11-17 (Crawled : 13:00) - globenewswire.com
AVTE M | $21.86 1.2% 1.19% 220K
|
Professional, Scientific, and T...
|
| O: -1.37%
H: 4.24%
C: -1.03%
av-101 treatment research hypertension therapeutics study phase 1
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.